Nature Reviews Gastroenterology & Hepatology

Article	Citations
Regulating protease homeostasis in irritable bowel syndrome	1203
Hybrid EASL Congress 2023	722
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity	609
Zolbetuximab treatment in metastatic gastric cancer	544
2023 FDA approvals in gastroenterology and hepatology	473
Western lifestyle, metaflammation and the cell of origin of colon cancer	422
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection	409
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis	369
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis	329
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology	326
Digestive Disease Week 2022	321
Mapping neuroimmune interactions in the gut	305
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	298
Leveraging diet to engineer the gut microbiome	295
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed	293
Artificial intelligence and automation in endoscopy and surgery	273
Nomenclature of HBV core protein-targeting antivirals	254
Single-cell RNA sequencing in pancreatic cancer	254
Hepatic IRF3 in glucose intolerance	248
Oral microbiome therapy efficacious for recurrent C. difficile infection	240
Wound healing in the colon	229
A crucial Fusobacterium nucleatum clade in colorectal cancer	205
GWAS reveals variants for alcohol-related hepatocellular carcinoma	199
Inflammatory bowel disease in pregnancy and breastfeeding	189
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges	185

Regulation and functional roles of chemokines in liver diseases	182
Metastatic pancreatic cancer and the liver	167
Decoding therapy resistance in liver tumours: a giant leap	163
A deep dive into the submerged ‘coeliac iceberg’	161
New understanding of hepatobiliary MRI	156
The global burden of coeliac disease: opportunities and challenges	155
Advancing on pancreatic cancer	146
Dietary carbohydrates and fats in nonalcoholic fatty liver disease	143
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract	141
Bacteriophages and their potential for treatment of gastrointestinal diseases	141
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation	141
Transglutaminase 2 inhibitor for coeliac disease	138
Integrated systems approach to identify environmental factors in intestinal inflammation	137
HDCA ameliorates NAFLD in mice	137
Hepatocyte-derived biomarkers in alcohol-related cirrhosis	135
Metabolic diseases in the East Asian populations	131
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook	130
Human intestinal B cells in inflammatory diseases	125
Therapeutic base editing in the adult liver	124
Lanifibranor and NASH resolution	121
Probiotics for preterms: sharing complex decision-making	116
Implications of the evolving knowledge of the genetic architecture of MASLD	110
The path to successful hepatitis C elimination in Spain	109
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases	107
Medical therapy of paediatric inflammatory bowel disease	106
Applications of organoids in regenerative medicine: a proof-of-concept for biliary injury	101
Estimating dietary intake from human stool DNA	99
Preventing the progression of cirrhosis to decompensation and death	98
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management	97
Characterizing the genomic landscape of colorectal cancer	97
Current and future colorectal cancer screening strategies	96
ECCO’24	95
Transforming the landscape of liver cancer detection and care	93
Yeast probiotics for the treatment of IBD	90
Author Correction: Hepatic immune regulation and sex disparities	90
A single-cell atlas of fibroblasts: one size does not fit all	90
NAFLD prevalence in older patients with T2DM	88
Phase III results for first-line treatment for metastatic colorectal cancer	88
Microbiota and colorectal cancer — controlling for confounders challenges associations	87
Publisher Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	87
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’	83
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance	83
Gut microbiome and autism spectrum disorder	82
Enteric nervous system transfers stress to the gut	82
Hepatic glucose metabolism in the steatotic liver	82
Artificial intelligence in liver cancer — new tools for research and patient management	80
GLP1R agonists in NAFLD: a promising therapy on the horizon	76
Hepatic inflammatory responses in liver fibrosis	73
Neutrophils as potential therapeutic targets in hepatocellular carcinoma	73
Foundations of gastrointestinal-based drug delivery and future developments	70

Immunoregulatory role of enteric glia	69
SMART cancer risk prediction	68
Liver dialysis in ACLF	67
The gut microbiome in feast and famine	65
AI predicts pancreatic cancer risk	65
Elucidating the transmission landscape of the human microbiome	64
Nifty new tools for microbiome treatment design	64
Gut bacteria go on record	63
Author Correction: Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel	62
International collaborative research to improve gallbladder cancer prevention	62
Digital biomarkers in human excreta	61
Postbiotics — when simplification fails to clarify	60
A new era in obesity management	59
MASLD as a non-communicable disease	59
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice	58
Future direction of total neoadjuvant therapy for locally advanced rectal cancer	58
Hepatitis E virus: from innate sensing to adaptive immune responses	57
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests	55
Revisiting fibrosis in inflammatory bowel disease: the gut thickens	53
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	53
Danger! P2Y14 receptor links cell death to liver fibrosis	47
Natural history of NAFLD: knowns and unknowns	47
Tirzepatide to treat obesity: phase III results	46
Publisher Correction: Publisher Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	46
Cathepsin S in liver fibrogenesis	45
Nivolumab plus chemotherapy for advanced gastric cancer and oesophageal adenocarcinoma	45
A novel pathomics signature for gastric cancer	43
Classifying compounds as prebiotics — scientific perspectives and recommendations	38
Origin of CAFs in colorectal cancer	37
The steatotic liver disease burden paradox: unravelling the key role of alcohol	37
Antibiotic-perturbed microbiota and the role of probiotics	36
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer	35
Therapeutic landscape and future direction of metastatic colorectal cancer	34
Cellular and molecular basis of proximal small intestine disorders	34
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors	33
Telemedicine for hepatitis C virus treatment in opioid treatment programmes	32
Commensal fungi in intestinal health and disease	32
Long-term normothermic liver perfusion	31
Alcohol-free and low-strength drinks: friend or foe?	29
Author Correction: Improving IBD outcomes in the era of many treatment options	29
Equitable partnerships and the path to inclusive, innovative and impactful human microbiome research	28
Justice, equity, diversity and inclusion in gastroenterology and hepatology	28
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus	27
Diet-driven microbiome restoration associated with cardiometabolic benefits	26
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	26
Author Correction: Current and future colorectal cancer screening strategies	26
A Roadmap for the Human Gut Cell Atlas	26
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease	25
Hippo signalling in the liver: role in development, regeneration and disease	24
New target and timing in PDAC immunotherapy?	24
Resmetirom safe for nonalcoholic fatty liver disease	24
Global epidemiology of cirrhosis — aetiology, trends and predictions	24
Digestive Disease Week 2023	23
Location, location, location — spatial insight into hepatic macrophage populations	23
Intermittent fasting for NASH and HCC in mice	23
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions	22
Envisioning how to advance the MASH field	22
Deciphering potential implications of dietary microplastics for human health	22
ECCO’25	22
A resource for the food microbiome and its links with the human microbiome	21
Food inequity and insecurity and MASLD: burden, challenges, and interventions	21
Elafibranor in primary biliary cholangitis	21
Human liver tissue in a mouse host	20
Nanoparticles in NAFLD therapeutics	20
Gastrointestinal health and the environment: a bidirectional relationship	20
Follow-up of SER-109 for recurrent C. difficile	20
Autocrine signalling discovery reveals potential therapeutic targets in NASH fibrosis	20
HCV direct-acting antiviral therapy adherence in people who inject drugs	19
RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer	19
Envisioning adalimumab for paediatric patients with ulcerative colitis	19
Advancing health equity: The Association of Black Gastroenterologists and Hepatologists	19
Amitriptyline as second-line treatment for IBS in primary care settings	19
Lactylation and HCC progression	18
COVID-19 and liver disease: where are we now?	18
Gastrointestinal post-acute COVID-19 syndrome	17
IL-17A-producing CD8+ T cells in pancreatic cancer	17
Early detection of pancreatic cancer using DNA-based molecular approaches	17
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology	16
Positioning therapies for the management of inflammatory bowel disease	16
Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology	16

The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease	16
Moving towards more patient-centred clinical trials in IBD	16
Biologic agents for IBD come of age as host–microbe interactions emerge	15
The need to integrate basic science and medicine in patient education resources	15
Paving the way: the road to be taken for proper NAFLD health care	15
Liver steatosis and fibrosis in China	14
Mapping the malignant transformation from polyps to CRC	14
Mucus secretion from colonic goblet cells is regulated by autophagy and ER stress	14
Elucidating the nutrient preferences of mouse gut bacteria	13
Combination treatment further extends survival	13
Elucidating the link between clonal haematopoiesis and chronic liver disease	13
Secretory IgA: controlling the gut microbiota	12
Author Correction: Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	12
Tolerance-inducing therapies in coeliac disease — mechanisms, progress and future directions	12
‘Dark matter’ beyond the bacteria in faecal microbiota transplantation	12
Host–pathobiont interactions in Crohn’s disease	12
Actions of thyroid hormones and thyromimetics on the liver	12
Fermented foods and gastrointestinal health: underlying mechanisms	11
AI-enabled ‘endo-histo-omics’: breaking down intestinal barriers in IBD	11
Paracellular permeability and tight junction regulation in gut health and disease	11
Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards	11
Neoadjuvant chemotherapy for operable colon cancer	11
Liquid biopsy guides anti-EGFR rechallenge in metastatic CRC	10
A bloody disgrace — time to change patient safety culture	10
Liver transplantation plus chemotherapy improved survival in patients with colorectal liver metastasis	10
Cellular triads in T cell liver tumours	10
The war on pancreatic cancer: progress and promise	10
Precision models in hepatocellular carcinoma	9
IgG4-related diseases of the digestive tract	9
Diversity, development and immunoregulation of enteric neurons	9
Mechanisms of metastatic colorectal cancer	9
Sex bias in clinical trials in gastroenterology and hepatology	9
Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy	9
Adjuvant nivolumab for resected gastroesophageal cancer	8
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments	8
Liver ischaemia–reperfusion injury: a new understanding of the role of innate immunity	8
Anatomy-preserving adjustable intragastric balloon is safe and promotes durable weight loss	8
Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation	8
Microbiome-targeted diets that alter immune status	7
Connecting with the community	7
Understanding the therapeutic toolkit for inflammatory bowel disease	7
CXCR2 inhibition in NASH-HCC	7
An expert panel Consensus Statement on ALD without experts by experience	7
Stigma: a major barrier to hepatitis B elimination	7
Liraglutide treatment in children with obesity	7
Rome Foundation Working Team Report on overlap in disorders of gut–brain interaction	7
NAFLD, MAFLD and obesity: brothers in arms?	6
The appendix and ulcerative colitis — an unsolved connection	6
No beneficial effect of G-CSF in treating ACLF	6
Crosstalk between enteric neurons and colorectal cancer stem cells influences self-renewal	6
Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders	6
Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?	6
Rhythmicity of infant microbiota and dietary effects	6
Effect of bariatric surgery on risk of oesophagogastric cancer	6
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications	6
Human hepatocyte organoids model early NAFLD	6
Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	6
Molecular landscape of NASH-HCC	6
Metabolic health across the ages: how microbiota members support our well-being	5
Filgotinib for ulcerative colitis	5
Pouchitis: pathophysiology and management	5
Author Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	5
Colonoscopy screening and risk of CRC	5
Contrasting aspects of human excreta	5
Exploring liver cancer biology through functional genetic screens	5
Machine perfusion of the liver: applications in transplantation and beyond	5
Combination therapy with methotrexate in paediatric Crohn’s disease	5
Fetal liver development and implications for liver disease pathogenesis	5
Standardized reporting of gastroenterology-related social media scholarship for career advancement	4
Safety of in utero exposure to maternal IBD pharmacotherapies	4
Lenvatinib plus EGFR inhibition for liver cancer	4
The promise of the gut microbiome as part of individualized treatment strategies	4
Gut feelings: mechanosensing in the gastrointestinal tract	4
Benign liver tumours: understanding molecular physiology to adapt clinical management	4
Hepatitis C testing, treatment and prevention in low- and middle-income country prisons	4
Liver fibrosis with methotrexate — an overestimated risk?	4
Mechanisms and pathophysiology of Barrett oesophagus	4
Friend or foe? The elusive role of hepatic stellate cells in liver cancer	4
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease	4
Novel interventions against alcohol-related liver disease	4
Transgender health care in the United States: legal, ethical and practical concerns for gastroenterologists in a changing landscape	4
CIDEB variants protect against liver disease	4
The immune microenvironment in gastric adenocarcinoma	4
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease	4
The metabolic nature of inflammatory bowel diseases	3
Reduction in colorectal cancer incidence by screening endoscopy	3
Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies	3
Biological Gradient of Chronic Hepatitis B	3
MASH-induced senescence and liver cancer	3
Therapeutic developments in pancreatic cancer	3
A prime role for PIEZO2 in DRG neurons in mechanosensation in the gut	3
TERT-expressing acinar cells implicated in early pancreatic tumour formation	3
COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology	3
Break the taboo with poo	3
Understanding the physiology of human defaecation and disorders of continence and evacuation	3